101 related articles for article (PubMed ID: 23755721)
21. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
22. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
[TBL] [Abstract][Full Text] [Related]
23. Nonlinear elimination kinetics of 5-fluoro-2'-deoxyuridine in isolated perfused rat liver and isolated hepatocytes.
Foth H; Kunellis EM; Müseler T; Kahl GF
J Pharmacol Exp Ther; 1990 Aug; 254(2):427-32. PubMed ID: 2143535
[TBL] [Abstract][Full Text] [Related]
24. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
Wang JX; Sun X; Zhang ZR
Eur J Pharm Biopharm; 2002 Nov; 54(3):285-90. PubMed ID: 12445558
[TBL] [Abstract][Full Text] [Related]
25. [Study on brain targeting 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes].
Zhang ZR; Wang JX
Yao Xue Xue Bao; 2001 Oct; 36(10):771-6. PubMed ID: 12579979
[TBL] [Abstract][Full Text] [Related]
26. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
27. Hydrolysis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine (FdUrd-C8) in rabbit and human plasma and its release from oily solution.
Fukushima S; Hayashi Y; Kawaguchi T; Kaneko M; Nakano M
J Pharmacobiodyn; 1989 Aug; 12(8):495-502. PubMed ID: 2559183
[TBL] [Abstract][Full Text] [Related]
28. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
Schwendener RA; Supersaxo A; Rubas W; Weder HG; Hartmann HR; Schott H; Ziegler A; Hengartner H
Biochem Biophys Res Commun; 1985 Jan; 126(2):660-6. PubMed ID: 3156589
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
30. Specificity of esterases and structure of prodrug esters. II. Hydrolytic regeneration behavior of 5-fluoro-2'-deoxyuridine (FUdR) from 3',5'-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity.
Kawaguchi T; Saito M; Suzuki Y; Nambu N; Nagai T
Chem Pharm Bull (Tokyo); 1985 Apr; 33(4):1652-9. PubMed ID: 2931191
[No Abstract] [Full Text] [Related]
31. Tumor-penetrating iRGD facilitates penetration of poly(floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy.
Li X; Zhong H; Zheng S; Mu J; Yu N; Guo S
J Control Release; 2024 May; 369():444-457. PubMed ID: 38575076
[TBL] [Abstract][Full Text] [Related]
32. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
34. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
Iigo M; Nishikata K; Nakajima Y; Hoshi A; Okudaira N; Odagiri H; De Clercq E
Biochem Pharmacol; 1989 Jun; 38(12):1885-9. PubMed ID: 2525905
[TBL] [Abstract][Full Text] [Related]
35. Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Eiseman JL; Yuan ZM; Eddington ND; Sentz DL; Callery PS; Egorin MJ
Cancer Chemother Pharmacol; 1996; 38(1):13-20. PubMed ID: 8603446
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary elimination and metabolism of 5-fluoro-2'-deoxyuridine in isolated perfused rat lung and lung slices.
Foth H; Hellkamp J; Kunellis EM; Kahl GF
Drug Metab Dispos; 1990; 18(6):1011-7. PubMed ID: 1981506
[TBL] [Abstract][Full Text] [Related]
37. Coupling of 5-fluoro 2'-deoxyuridine to lactosaminated poly-l-lysine: an approach to a regional, non-invasive chemotherapy of liver micrometastases.
Di Stefano G; Busi C; Camerino A; Derenzini M; Trerè D; Fiume L
Biochem Pharmacol; 2001 Feb; 61(4):459-65. PubMed ID: 11226380
[TBL] [Abstract][Full Text] [Related]
38. Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Peng Y; Yu W; Li E; Kang J; Wang Y; Yang Q; Liu B; Zhang J; Li L; Wu J; Jiang J; Wang Q; Chang J
J Med Chem; 2016 Apr; 59(8):3661-70. PubMed ID: 27022837
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
[TBL] [Abstract][Full Text] [Related]
40. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
